What should we make of claims that weight-loss shots can cause blindness?
On the same day the FDA said weight-loss shots could harm your eyes, Eli Lilly closed up 4.3%. Looks like the market didn’t take the warning seriously at all 😂
On November 9, the FDA required all GLP-1 drugs to update their prescribing information. That includes semaglutide, tirzepatide, and the weight-loss pill Lilly just got approved this year. The update adds a risk of the rare eye condition NAION, which can cause permanent vision loss in one eye in severe cases.
That same day, Lilly put out a press release saying that in a Phase 3 trial, its weight-loss pill Foundayo reduced the number of sleep apnea episodes by more than 40%. The company plans to ask the FDA to approve this new use before the end of the year.
Novo Nordisk was also up 2.7% that day.
The FDA added this warning to the Warnings and Precautions section of the prescribing information. It is not the highest-level, boxed warning.
I translated the original FDA notice. The FDA’s own data show 10 cases among 78,000 people who received injections. That figure is based on its review of 126 clinical trials.
The European Medicines Agency added this condition to semaglutide’s prescribing information last June, classifying it as very rare—affecting at most one in 10,000 people.
The FDA’s advice for people receiving injections is still that anyone who has had this condition before should talk to their doctor about whether to continue treatment.
On the same day the FDA said weight-loss shots could harm your eyes, Eli Lilly closed up 4.3%. Looks like the market didn’t take the warning seriously at all 😂
On November 9, the FDA required all GLP-1 drugs to update their prescribing information. That includes semaglutide, tirzepatide, and the weight-loss pill Lilly just got approved this year. The update adds a risk of the rare eye condition NAION, which can cause permanent vision loss in one eye in severe cases.
That same day, Lilly put out a press release saying that in a Phase 3 trial, its weight-loss pill Foundayo reduced the number of sleep apnea episodes by more than 40%. The company plans to ask the FDA to approve this new use before the end of the year.
Novo Nordisk was also up 2.7% that day.
The FDA added this warning to the Warnings and Precautions section of the prescribing information. It is not the highest-level, boxed warning.
I translated the original FDA notice. The FDA’s own data show 10 cases among 78,000 people who received injections. That figure is based on its review of 126 clinical trials.
The European Medicines Agency added this condition to semaglutide’s prescribing information last June, classifying it as very rare—affecting at most one in 10,000 people.
The FDA’s advice for people receiving injections is still that anyone who has had this condition before should talk to their doctor about whether to continue treatment.

